Dual-targeted treatment for inflammatory bowel disease:Whether fecal microbiota transplantation can be an important part of it  

作　　者：Zi-Ning Zhang Li-Xuan Sang 

机构地区：[1]Department of Gastroenterology,The Shengjing Hospital of China Medical University,Shenyang 110022,Liaoning Province,China

出　　处：《World Journal of Gastroenterology》2024年第36期4025-4030,共6页世界胃肠病学杂志（英文版）

基　　金：Supported by The Science and Technology Plan of Liaoning Province,China,No.2022JH2/101500063.

摘　　要：Inflammatory bowel disease(IBD)is a chronic gastrointestinal inflammatory disease.With the emergence of biologics and other therapeutic methods,two biologics or one biologic combined with a novel small-molecule drug has been proposed in recent years to treat IBD.Although treatment strategies for IBD are being optimized,their efficacy and risks still warrant further consideration.This editorial explores the current risks associated with dual-targeted treatment for IBD and the great potential that fecal microbiota transplantation(FMT)may have for use in combination therapy for IBD.We are focused on addressing refractory IBD or biologically resistant IBD based on currently available dual-targeted treatment by incorporating FMT as part of this dual-targeted treatment.In this new therapy regimen,FMT represents a promising combination therapy.

关 键 词：Gut microbiota Inflammatory bowel disease Fecal microbiota transplantation Dual-targeted treatment Combination treatment 

分 类 号：R574[医药卫生—消化系统]